3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
2
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, T-Cell
1
Lymphoma
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Monocytic, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Erythroblastic, Acute
1
Leukemia
1
Interventions
Cytarabine
32
Cyclophosphamide
16
Busulfan
16
fludarabine phosphate
14
Peripheral Blood Stem Cell Transplantation
13
Filgrastim
13
Idarubicin
11
Etoposide
11
Antilymphocyte Serum
10
Cyclosporine
9
Mitoxantrone
8
Radiotherapy
7
Methotrexate
7
Daunorubicin
7
Whole-Body Irradiation
5
Tacrolimus
5
Cord Blood Stem Cell Transplantation
5
Clofarabine
5
Mycophenolic Acid
4
Methylprednisolone
4
Flow Cytometry
4
Arsenic Trioxide
4
aldesleukin
3
Topotecan
3
Thiotepa
3
Melphalan
3
Imatinib Mesylate
3
Gemtuzumab
3
Cytogenetic Analysis
3
Cyclosporins
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Leukemia, Megakaryoblastic, Acute
×
BI 6727
×
Clear all
NCT02527174
2017-04-05
VIAC
University of Alberta
Phase 1
Withdrawn